ATXI · Avenue Therapeutics, Inc.
$0.39
+0.03 (+8.87%)
At close · Jul 30
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“substantial doubt about the Company's ability to continue as a going concern exists.”View the 10-Q filed May 8, 2026
Market Cap
$824,400
Shares
3.29M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | CEO | $1,082,129 |
| Joseph Vazzano | CFO | $441,330 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | CEO | $443,027 |
| Joseph Vazzano | CFO | $214,890 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | CEO | $639,783 |
| Joseph Vazzano | CFO | $258,779 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | CEO | $1,594,633 |
| Joseph Vazzano | CFO | $354,528 |